AbbVie Inc. ABBV announced that the FDA has accepted its new drug application (NDA) for its oral investigational JAK inhibitor, upadacitinib, and also granted a priority review to the same. The company is seeking an approval for upadacitinib for treating adult patients with moderate to severe rheumatoid arthritis (RA). A...